News Amgen's Five Prime takeover delivers gastric cancer win Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.
News Five Prime eyes financing after positive results with stomac... Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not
News European Commission approves 2nd IPCEI to sum of €403m The European Commission has approved, under EU State aid rules, the second health-related IPCEI to support innovations in medical devices.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face